News

Inventa announces first license deal

17th February 2020, Nottingham, UK - Specialist drug development company Inventa Therapeutics Ltd (Inventa) has announced the completion of an exclusive license and collaboration deal with Cellix Bio Private Ltd (Cellix), a bio pharma company based in Hyderabad, India. The subject of the agreement is a novel pre-clinical stage pro-drug of Mesalamine (CLX-103a) to treat Ulcerative Colitis and Crohn's disease. Mesalamine is one of two current treatments of choice for Ulcerative Colitis and Crohn's disease and nine brands of this generic drug are currently on the market. Current formulations of Mesalamine cause significant adverse side effects which the patented Cellix pro-drug formulation is designed to minimise. Under the terms of the deal, Cellix will provide Inventa with access to all the Cellix chemistry, existing pre-clinical data and know-how. In return, Inventa will be responsible for all preclinical and clinical development activities